TCR or antigen binding fragment thereof and application thereof
By developing TCR targeting the polypeptide-HLA-A1101 complex, the problem of insufficient recognition and killing ability of KRAS gene mutant tumor cells in the prior art is solved, and efficient recognition and killing of KRAS-G12V mutant cells is achieved, which has improved the Effects of specific cancer treatment.
Patent Information
- Application Number
- CN202411307696.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-12-03
AI Technical Summary
The existing CAR-T therapy technology limits its application prospects due to limited specific targets when targeting solid tumors, especially for tumor cells related to KRAS gene mutations, which are difficult to effectively identify and kill.
A TCR targeting the polypeptide-HLA-A1101 complex, containing specific alpha- and beta-chain variable region sequences, is developed, capable of specifically binding to the KRAS-G12V mutation site, thereby stimulating T cell activation and mediating the Killing of tumor cells expressing the KRAS-G12V mutant gene.
It provides strong specific binding ability to KRAS-G12V mutant polypeptide, can effectively kill tumor cells expressing the KRAS-G12V mutant gene, significantly improving the specific cancers such as pancreatic cancer, colon cancer, endometrial cancer, lung cancer, etc. Treatment effect.
Smart Images

Figure CN119060165A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of T cell immunotherapy drugs, and specifically relates to a TCR or an antigen binding fragment thereof and applications thereof. Background Art
[0002] With the progress of research in the biomedical field, the target selection of T cell immunotherapy for malignant solid tumors has been constantly evolving, from the initial lineage antigens to viral antigens. With the emergence of high-throughput sequencing technology in recent years, targeting individual tumor mutations has become the focus of the new generation of T cell therapy.
[0003] T cell therapy currently mainly includes TCR-T and CAR-T treatment methods. At present, CAR-T technology treatment has played a significant role in the treatment of blood tumors such as leukemia and lymphoma, greatly improving the survival rate and quality of life of patients. However, for solid tumors, CAR-T treatment methods have limited specific targets, which greatly limits its application prospects. TCR-T technology is different from CAR-T cell technology. TCR is a characteristic marker on the surface of all T cells, which binds to CD3 with non-covalent bonds to form a TCR-CD3 complex. In peripheral blood, 90%-95% of T cells express TCR. T cells with genetically modified TCR can specifically recognize antigen molecules on the surface of tumor cells, and then produce immune responses against tumor cells. Currently, in human cancer, the KRAS gene is one of the most famous oncogenes in the field of oncology. KRAS gene mutations (KRAS-G12C mutation, KRAS-G12V mutation, KRAS-G12V mutation, etc.) appear in nearly 90% of pancreatic cancer, 30%-40% of colon cancer, 17% of endometrial cancer, 15%-20% of lung cancer including lobular lung cancer, as well as bile duct cancer, cervical cancer, bladder cancer, etc.
[0004] Based on the above situation, there is a need for a TCR that can specifically bind to the KRAS mutant polypeptide and mediate T cells to kill KRAS mutant tumor cells. Summary of the invention
[0005] The present invention develops a TCR that can target and specifically recognize the KRAS-G12V mutation site, which specifically binds to the complex of the KRAS-G12V mutant polypeptide and HLA, thereby stimulating T cell activation and mediating T cell killing of tumor cells expressing the KRAS-G12V mutant gene.
[0006] In order to achieve the above object, the present invention can adopt the following technical solutions:
[0007] In one aspect, the present invention provides a TCR targeting a polypeptide-HLA-A1101 complex, which can be selected from any one of the following TCRs:
[0008] (a) a first TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 1, an α chain CDR2 as shown in SEQ ID NO: 2, and an α chain CDR3 as shown in SEQ ID NO: 3; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 9, a β chain CDR2 as shown in SEQ ID NO: 10, and a β chain CDR3 as shown in SEQ ID NO: 11;
[0009] (b) a second TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 33, an α chain CDR2 as shown in SEQ ID NO: 34, and an α chain CDR3 as shown in SEQ ID NO: 35; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 41, a β chain CDR2 as shown in SEQ ID NO: 42, and a β chain CDR3 as shown in SEQ ID NO: 43;
[0010] (c) a third TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 65, an α chain CDR2 as shown in SEQ ID NO: 66, and an α chain CDR3 as shown in SEQ ID NO: 67; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 73, a β chain CDR2 as shown in SEQ ID NO: 74, and a β chain CDR3 as shown in SEQ ID NO: 75;
[0011] (d) A fourth TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 97, an α chain CDR2 as shown in SEQ ID NO: 98, and an α chain CDR3 as shown in SEQ ID NO: 99; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 105, a β chain CDR2 as shown in SEQ ID NO: 106, and a β chain CDR3 as shown in SEQ ID NO: 107.
[0012] Another aspect of the present invention provides an antigen-binding fragment comprising the TCR of the present invention.
[0013] In another aspect, the present invention provides a polynucleotide encoding the TCR of the present invention.
[0014] In another aspect, the present invention provides an expression vector comprising the polynucleotide of the present invention.
[0015] In another aspect, the present invention provides an engineered cell comprising the expression vector of the present invention.
[0016] In another aspect, the present invention provides a pharmaceutical composition comprising the TCR of the present invention, the antigen-binding fragment of the present invention, the polynucleotide of the present invention, the expression vector of the present invention, or the engineered cell of the present invention, and a pharmaceutically acceptable carrier and / or diluent.
[0017] In another aspect, the present invention further provides a use of the TCR of the present invention, or the antigen-binding fragment of the present invention, or the polynucleotide of the present invention, or the expression vector of the present invention, or the engineered cell of the present invention in the preparation of a reagent or kit for detecting tumor cells expressing the KRAS-G12V mutation.
[0018] In another aspect, the present invention also provides a use of the TCR of the present invention, or the antigen-binding fragment of the present invention, or the polynucleotide of the present invention, or the expression vector of the present invention, or the engineered cell of the present invention in the preparation of a drug for treating cancer; cancer includes pancreatic cancer, colon cancer, endometrial cancer, lung cancer, bile duct cancer, cervical cancer, or bladder cancer
[0019] The beneficial effect of the present invention is that the TCR provided by the present invention has strong specificity for the KRAS-G12V mutant polypeptide and can mediate T cells to kill KRAS-G12V mutant tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 To detect KRAS in different samples G12V Specific T cell status;
[0021] Figure 2 To detect the expression of TCR in Jurkat by flow cytometry;
[0022] Figure 3 Functional affinity test results of TCR;
[0023] Figure 4 is the expression of TCR by primary T cells;
[0024] Figure 5 For KRAS G12V Expression of CD137 after peptide stimulation of T cells;
[0025] Figure 6 For KRAS G12V IFN-gamma secretion after peptide stimulation of T cells;
[0026] Figure 7 TCR-T cells expressing endogenous KRAS G12V Cell co-incubation of genes;
[0027] Figure 8 TCR-T cells expressing endogenous KRASG12V Gene-transduced cells (not transduced with A1101) were co-incubated to detect the cell killing ability;
[0028] Fig. 9 TCR-T cells expressing endogenous KRAS G12V The cells with the gene (after transduction with A1101) were co-cultured to detect the cell killing ability;
[0029] in, Figure 3 , Figure 5 and Figure 6 The X-axis in the figure shows the peptide concentration Log10. DETAILED DESCRIPTION
[0030] The terms used herein are only used to describe specific embodiments and are not intended to limit the present disclosure. Unless the context has a significantly different meaning, expressions in the singular include expressions in the plural. As used herein, it should be understood that terms such as "include", "have", "include" are intended to indicate the presence of features, numbers, operations, components, parts, elements, materials or combinations. The terms of the present invention are disclosed in the specification, and are not intended to exclude the possibility that one or more other features, numbers, operations, components, parts, elements, materials or combinations thereof may exist or may be added. As used herein, " / " may be interpreted as "and" or "or", depending on the circumstances.
[0031] In the present invention, the term "antigen binding fragment" refers to antigen binding fragments of TCR and TCR analogs, which generally include at least part of the antigen binding region or variable region of the parent TCR, such as one or more CDRs. The fragment of TCR retains at least some of the binding specificity of the parent TCR.
[0032] The embodiment of the present invention provides a TCR targeting a polypeptide-HLA-A1101 complex, which can be selected from any one of the following TCRs:
[0033] (a) a first TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 1, an α chain CDR2 as shown in SEQ ID NO: 2, and an α chain CDR3 as shown in SEQ ID NO: 3; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 9, a β chain CDR2 as shown in SEQ ID NO: 10, and a β chain CDR3 as shown in SEQ ID NO: 11;
[0034] (b) a second TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 33, an α chain CDR2 as shown in SEQ ID NO: 34, and an α chain CDR3 as shown in SEQ ID NO: 35; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 41, a β chain CDR2 as shown in SEQ ID NO: 42, and a β chain CDR3 as shown in SEQ ID NO: 43;
[0035] (c) a third TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 65, an α chain CDR2 as shown in SEQ ID NO: 66, and an α chain CDR3 as shown in SEQ ID NO: 67; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 73, a β chain CDR2 as shown in SEQ ID NO: 74, and a β chain CDR3 as shown in SEQ ID NO: 75;
[0036] (d) A fourth TCR, comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO: 97, an α chain CDR2 as shown in SEQ ID NO: 98, and an α chain CDR3 as shown in SEQ ID NO: 99; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO: 105, a β chain CDR2 as shown in SEQ ID NO: 106, and a β chain CDR3 as shown in SEQ ID NO: 107.
[0037] It should be noted that the CDR3 of the α chain and β chain in the above TCR belongs to the hypervariable region of the variable region. When the TCR recognizes the MHC-antigen peptide complex, CDR3 directly binds to the antigen peptide, which directly affects the TCR's ability to recognize the KRAS-G12V mutation. The hypervariable regions of the α chain and β chain of the TCR also include two hypervariable regions, CDR1 and CDR2. The CDR1 and CDR2 hypervariable regions are relatively stable relative to CDR3. When the TCR recognizes the MHC-antigen peptide complex, the CDR1 and CDR2 hypervariable regions recognize and bind to the side walls of the antigen binding groove of the MHC molecule.
[0038] In some specific examples, the above TCR may also include other sequences, as follows:
[0039] In the first TCR, the α chain variable region further comprises: one or more of the α chain FR1 as shown in SEQ ID NO: 4, the α chain FR2 as shown in SEQ ID NO: 5, the α chain FR3 as shown in SEQ ID NO: 6, and the α chain FR4 as shown in SEQ ID NO: 7; the β chain variable region further comprises: one or more of the β chain FR1 as shown in SEQ ID NO: 12, the β chain FR2 as shown in SEQ ID NO: 13, the β chain FR3 as shown in SEQ ID NO: 14, and the β chain FR4 as shown in SEQ ID NO: 15;
[0040] In the second TCR, the α chain variable region further comprises: one or more of the α chain FR1 as shown in SEQ ID NO: 36, the α chain FR2 as shown in SEQ ID NO: 37, the α chain FR3 as shown in SEQ ID NO: 38, and the α chain FR4 as shown in SEQ ID NO: 39; the β chain variable region further comprises: one or more of the β chain FR1 as shown in SEQ ID NO: 44, the β chain FR2 as shown in SEQ ID NO: 45, the β chain FR3 as shown in SEQ ID NO: 46, and the β chain FR4 as shown in SEQ ID NO: 47;
[0041] In the third TCR, the α chain variable region further comprises: one or more of the α chain FR1 as shown in SEQ ID NO: 68, the α chain FR2 as shown in SEQ ID NO: 69, the α chain FR3 as shown in SEQ ID NO: 70, and the α chain FR4 as shown in SEQ ID NO: 71; the β chain variable region further comprises: one or more of the β chain FR1 as shown in SEQ ID NO: 76, the β chain FR2 as shown in SEQ ID NO: 77, the β chain FR3 as shown in SEQ ID NO: 78, and the β chain FR4 as shown in SEQ ID NO: 79;
[0042] In the fourth TCR, the α chain variable region also includes: one or more of α chain FR1 as shown in SEQ ID NO: 100, α chain FR2 as shown in SEQ ID NO: 101, α chain FR3 as shown in SEQ ID NO: 102 and α chain FR4 as shown in SEQ ID NO: 103; the β chain variable region also includes: one or more of β chain FR1 as shown in SEQ ID NO: 108, β chain FR2 as shown in SEQ ID NO: 109, β chain FR3 as shown in SEQ ID NO: 110 and β chain FR4 as shown in SEQ ID NO: 111.
[0043] It should be noted that the FR (FR1, FR2, FR3, FR4) in the above-mentioned TCR is a framework region, which is used to connect the CDR region and is relatively stable. In addition to selecting the above-mentioned sequences, the FR region in the above-mentioned first TCR can also select sequences with a sequence identity of ≥80% or more with the above-mentioned FR1, FR2, FR3 and FR4, such as sequences of ≥80%, 85%, 90% or 95%, and the source can be mouse or human (but other sources, such as rabbit, pig and other animal sources are not excluded). In some specific implementations, the sequences of the FR regions of the above-mentioned α chain and β chain and the sequences of the CDR regions can be arranged according to FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, respectively constituting the α chain variable region and β chain variable region of the two TCRs.
[0044] In some specific examples, in the above TCR:
[0045] The α chain variable region of the first TCR may include the sequence shown in SEQ ID NO: 8; the β chain variable region may include the sequence shown in SEQ ID NO: 16;
[0046] The α chain variable region of the second TCR may comprise the sequence shown in SEQ ID NO: 40; the β chain variable region may comprise the sequence shown in SEQ ID NO: 48;
[0047] The α chain variable region of the third TCR may comprise the sequence shown in SEQ ID NO: 72; the β chain variable region may comprise the sequence shown in SEQ ID NO: 80;
[0048] The α chain variable region of the fourth TCR may include the sequence shown in SEQ ID NO: 104; the β chain variable region may include the sequence shown in SEQ ID NO: 112.
[0049] It should be noted that the sequences of the α chain variable regions or β chain variable regions of the above-mentioned first TCR, second TCR, third TCR and fourth TCR can also be sequences with an identity ≥80% with the above sequences, such as sequences with an identity ≥80%, 85%, 90%, 95%.
[0050] It should also be noted that, in addition to the above-mentioned α chain variable region and β chain variable region, the α chain also includes an α chain constant region, and the β chain also includes a β chain constant region. The sources of the α chain constant region and the β chain constant region can be mouse, human or human-mouse chimera (but other sources, such as rabbit, pig and other animal sources are not excluded), which are almost no mutation regions. For example, the amino acid sequences of the α chain constant region and the β chain constant region of the first TCR can be shown as SEQ ID NO: 129 and SEQ ID NO: 130, respectively; the amino acid sequences of the α chain constant region and the β chain constant region of the second TCR can be shown as SEQ ID NO: 131 and SEQ ID NO: 132, respectively; the amino acid sequences of the α chain constant region and the β chain constant region of the third TCR can be shown as SEQ ID NO: 133 and SEQ ID NO: 134, respectively; the amino acid sequences of the α chain constant region and the β chain constant region of the fourth TCR can be shown as SEQ ID NO: 135 and SEQ ID NO: 136, respectively.
[0051] It should also be noted that, in the above-mentioned TCR, regarding the sources of the variable region and constant region of the α chain or β chain, the α chain variable region or β chain variable region is from mouse or human (but other sources, such as rabbit, pig and other animal sources are not excluded), and the source of the α chain or β chain constant region may be the same as or different from the source of the α chain or β chain variable region.
[0052] An embodiment of the present invention further provides an antigen binding fragment, which comprises the TCR of the present invention.
[0053] An embodiment of the present invention also provides a polynucleotide encoding the TCR of the present invention.
[0054] It should be noted that any polynucleotide that can encode the TCR of the present invention is a polynucleotide of the present invention.
[0055] In some specific examples, the polynucleotide is selected from any one of the following nucleotides:
[0056] (a) the polynucleotide encoding the first TCR comprises a sequence as shown in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 26 or SEQ ID NO: 27; specifically, the above sequence comprises a polynucleotide encoding the first TCR α chain variable region (such as a sequence as shown in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19) and a polynucleotide encoding the first TCR β chain variable region (such as a sequence as shown in SEQ ID NO: 25, SEQ ID NO: 26 or SEQ ID NO: 27);
[0057] (b) the polynucleotide encoding the second TCR comprises a sequence as shown in SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 57, SEQ ID NO: 58 or SEQ ID NO: 59; specifically, the above sequence comprises a polynucleotide encoding the second TCR α chain variable region (such as a sequence as shown in SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51) and a polynucleotide encoding the second TCR β chain variable region (such as a sequence as shown in SEQ ID NO: 57, SEQ ID NO: 58 or SEQ ID NO: 59);
[0058] (c) the polynucleotide encoding the third TCR comprises a sequence as shown in SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91; specifically, the above sequence comprises a polynucleotide encoding the variable region of the second TCR α chain (such as a sequence as shown in SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83) and a polynucleotide encoding the variable region of the second TCR β chain (such as a sequence as shown in SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91);
[0059] (d) The polynucleotide encoding the fourth TCR includes a sequence as shown in SEQIDNO:113, SEQIDNO:114, SEQIDNO:115, SEQIDNO:121, SEQIDNO:122 or SEQIDNO:123; specifically, the above sequence includes a polynucleotide encoding the variable region of the second TCR α chain (a sequence as shown in SEQIDNO:113, SEQIDNO:114, SEQIDNO:115) and a polynucleotide encoding the variable region of the second TCR β chain (a sequence as shown in SEQIDNO:121, SEQIDNO:122 or SEQIDNO:123).
[0060] In some specific examples, in the above polynucleotides:
[0061] (a) the polynucleotide encoding the first TCR further comprises one or more of the sequences shown in SEQ ID NO: 20 to SEQ ID NO: 23, SEQ ID NO: 28 to SEQ ID NO: 31; specifically, the polynucleotide encoding the first TCR may comprise a polynucleotide encoding the FR region of the α chain variable region and the β chain variable region in addition to the polynucleotide encoding the CDR region of the α chain variable region and the β chain variable region;
[0062] (b) the polynucleotide encoding the second TCR further comprises one or more of the sequences shown in SEQ ID NO: 52 to SEQ ID NO: 55 and SEQ ID NO: 60 to SEQ ID NO: 63; specifically, the polynucleotide encoding the second TCR may comprise a polynucleotide encoding the FR region of the α chain variable region and the β chain variable region in addition to the polynucleotide encoding the CDR region of the α chain variable region and the β chain variable region;
[0063] (c) the polynucleotide encoding the third TCR further comprises one or more of the sequences shown in SEQ ID NO: 84 to SEQ ID NO: 87 and SEQ ID NO: 92 to SEQ ID NO: 95; specifically, the polynucleotide encoding the third TCR may comprise polynucleotides encoding the FR regions of the α chain variable region and the β chain variable region in addition to the polynucleotides encoding the CDR regions of the α chain variable region and the β chain variable region;
[0064] (d) The polynucleotide encoding the fourth TCR also contains one or more of the sequences shown in SEQ ID NO: 116 to SEQ ID NO: 119, SEQ ID NO: 124 to SEQ ID NO: 127; specifically, in addition to the polynucleotide encoding the CDR region of the α chain variable region and the β chain variable region, the above-mentioned polynucleotide encoding the fourth TCR may also contain a polynucleotide encoding the FR region of the α chain variable region and the β chain variable region.
[0065] In some specific examples, in the above polynucleotides:
[0066] The polynucleotide encoding the first TCR may comprise the sequences shown in SEQ ID NO: 24 and SEQ ID NO: 32;
[0067] The polynucleotide encoding the second TCR may comprise the sequences shown in SEQ ID NO: 56 and SEQ ID NO: 64;
[0068] The polynucleotide encoding the third TCR may comprise the sequences shown in SEQ ID NO: 88 and SEQ ID NO: 96;
[0069] The polynucleotide encoding the fourth TCR may include the sequences shown as SEQ ID NO: 120 and SEQ ID NO: 128.
[0070] It should be noted that the above-mentioned polynucleotides are polynucleotides encoding the variable regions of the corresponding TCRs.
[0071] It should also be noted that any of the above-mentioned polynucleotides may also contain modified nucleotides thereof, such as a sequence after codon optimization as shown in SEQIDNO:24 and SEQIDNO:32; another example, a sequence after codon optimization as shown in SEQIDNO:56 and SEQIDNO:64; another example, a sequence after codon optimization as shown in SEQIDNO:88 and SEQIDNO:96; another example, a sequence after codon optimization as shown in SEQIDNO:120 and SEQIDNO:128.
[0072] An embodiment of the present invention further provides an expression vector comprising the polynucleotide of the present invention.
[0073] It should be noted that the above expression vector is selected from any one of a lentiviral expression vector, a retroviral expression vector, an adenoviral expression vector, an adeno-associated viral expression vector, a DNA vector, an RNA vector and a plasmid. In addition, the lentiviral vector can be selected from the following groups: human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), visna-maedivirus (VMV) virus, caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and simian immunodeficiency virus (SIV).
[0074] The embodiment of the present invention further provides an engineered cell, which comprises the expression vector of the present invention.
[0075] It should be noted that the engineered cells can be host cells, into which the above expression vector is introduced to encode a TCR polypeptide; or they can be T cells, into which the above expression vector (loaded with the target gene) is transfected to obtain TCR-T cells for the recognition and killing of the KRAS-G12V mutant polypeptide.
[0076] An embodiment of the present invention also provides a pharmaceutical composition, which comprises the TCR of the present invention or the antigen-binding fragment of the present invention or the polynucleotide of the present invention or the expression vector of the present invention or the engineered cell of the present invention, and a pharmaceutically acceptable carrier and / or diluent.
[0077] It should be noted that pharmaceutically acceptable carriers and / or diluents refer to the above-mentioned TCR or the above-mentioned antigen binding fragment or the above-mentioned polynucleotide or the above-mentioned expression vector or the above-mentioned engineered cells can be prepared into various desired dosage forms. For example, tablets, powders, pills, powders, granules, fine granules, soft / hard capsules, film coatings, pellets, sublingual tablets, ointments, etc. can be listed as oral agents, and injections, suppositories, transdermal agents, ointments, plasters, external liquids, etc. can be listed as non-oral agents. Those skilled in the art can select appropriate dosage forms according to the route of administration and the subject of administration.
[0078] Use of the TCR of the present invention, or the antigen-binding fragment of the present invention, or the polynucleotide of the present invention, or the expression vector of the present invention, or the engineered cell of the present invention in the preparation of a reagent or kit for detecting tumor cells expressing the KRAS-G12V mutation.
[0079] It should be noted that the kits involved can be divided into various small boxes, which are then filled with various detection reagents. The detection reagents and detection kits can be indirectly or directly applied to various malignant tumors expressing KRAS-G12V mutations, such as pancreatic tumors, colorectal malignancies, endometrial malignancies, lung malignancies, bile duct malignancies, cervical malignancies, etc.
[0080] Use of the TCR of the present invention, or the antigen-binding fragment of the present invention, or the polynucleotide of the present invention, or the expression vector of the present invention, or the engineered cell of the present invention in the preparation of a drug for treating cancer; cancer includes pancreatic cancer, colon cancer, endometrial cancer, lung cancer, bile duct cancer, cervical cancer, or bladder cancer.
[0081] In some specific examples, in the above applications, the drugs used to treat cancer include protein drugs, ADC drugs or TCR-T cell drugs.
[0082] It should be noted that in the above application, for the HLA-A*11:01-restricted T cell epitope polypeptide of the KRAS-G12V mutation, HLA-A1101 with stronger affinity is selected, that is, the polypeptide after the KRAS-G12V mutation is presented by the HLA-A1101 molecule, but the selection of other HLA molecules, such as the HLA-A11 series alleles, is not excluded.
[0083] It should also be noted that in the above applications, TCR selects any one of the above two TCRs; polynucleotides select any one of the above two polynucleotides. In the above applications, TCR or antigen binding fragment or polynucleotide or expression vector or engineered cell can be added with excipients to form a drug, or can be used in combination with other active drugs or detection agents, such as some existing chemotherapy drugs, such as alkylating agents, antimetabolites, antitumor antibiotics, plant anticancer drugs, hormones, immune preparations, etc.; it can also be combined with surgery. The specific situation depends on the tumor condition. Medication or combined medication.
[0084] It should also be noted that in the above application, the amino acid sequence of the KRAS-G12V mutant polypeptide is shown in SEQ ID NO: 131.
[0085] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific examples, but the content of the present invention is not limited to the following examples.
[0086] In the following examples, the variable region amino acid sequences and encoded nucleotide sequences of four TCRs are shown in Tables 1 and 2, respectively.
[0087] Table 1 Sequences of the first TCR and the second TCR
[0088]
[0089] Table 2 The third TCR and fourth TCR sequences
[0090]
[0091] In addition, the constant region amino acid sequences of the four TCRs are shown in 3 below.
[0092] Table 3 Constant region amino acid sequences of four TCRs (the four TCR constant regions are the same)
[0093] α chain constant region amino acids SEQ ID NO:129 β chain constant region amino acids SEQ ID NO:130
[0094] In the following examples, the KRAS-G12V mutant polypeptide (abbreviated as KRAS-G12V) used has a sequence as shown in SEQ ID NO: 131, which was commissioned to Kingrise Biotech Co., Ltd. for synthesis.
[0095] In the following example, the tetramer of KRAS-G12V / HLA-A1101 uses the QuickSwitch TMThe Quant Tetramer Kit is prepared, and the reagent can be easily prepared in the laboratory. The specific preparation process is as follows: 1ul KRAS-G12 peptide and 1ul KRAS-G12V peptide replacement agent are added to 50ul QuickSwitchTetramer to obtain KRAS-G12V / HLA-A1101 tetramer, which is placed at room temperature for 4 hours and stored at 4°C for use.
[0096] In the following examples, the gene amplification, sequencing and analysis methods involved are performed with reference to the methods described in paragraphs
[0068] to
[0075] of the specification of the patent publication CN115109139A.
[0097] In the following examples, the human PBMC cells and human peripheral blood involved were derived from volunteers.
[0098] 1. KRAS G12V Stimulation and expansion of (KRAS-G12V)-reactive T cells
[0099] (1) Isolation and storage of peripheral blood mononuclear cells (PBMCs): Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors by density gradient centrifugation and then frozen in liquid nitrogen until needed.
[0100] (2) Generation of autologous monocyte-derived dendritic cells (moDCs): Using EasySep TM Monocytes were enriched from PBMCs using a CD14+ cell selection kit (STEMCELL Technologies); these monocytes were cultured in dendritic cell medium and supplemented with fresh complete medium every other day; on day 6, moDCs were cryopreserved in liquid nitrogen for subsequent experiments.
[0101] (3) Isolation and culture of naive CD8+ T cells: Naive CD8+ T cells were isolated from PBMCs using the Naive CD8+ T Cell Isolation Kit (STEMCELL Technologies). These cells were then co-cultured with moDCs pre-loaded with KRAS-G12V (final concentration of 10 μM). Before co-culture, moDCs were activated with lipopolysaccharide (LPS, 10 ng / mL) and interferon γ (IFN-γ, 100 U / mL) for 16 hours to enhance antigen presentation. Co-culture was performed in a 48-well plate, and the ratio of naive CD8+ T cells to moDCs was 2:1, i.e., each well contained 5E 5 (5×10^5) T cells, 2.5E 5(2.5×10^5) moDCs; To promote the survival of naive T cells, 30ng / mL IL-21 was supplemented in the culture medium.
[0102] (4) T cell expansion: The culture medium was replaced every three days, and IL-7 and IL-15 (5 ng / mL each) were added to support the growth and differentiation of T cells. The entire culture process lasted for 14 days. The stimulation product was then subjected to a second round of stimulation to further activate and amplify KRAS G12V Specific T cells; after flow cytometry detection, it was found that HD-1, HD-2, HD-3 and HD-4 samples had different frequencies of KRAS-G12V-specific T cells (see Figure 1 ).
[0103] (5) KRAS G12V Identification of specific T cells and TCR cloning: The final culture product is used to identify KRAS G12V Specific T cells were cloned and sequenced for TCR genes; TCR gene sequences were successfully obtained through single-cell sorting and sequencing, and the variable region sequences of KT18, KT19, KT20 and KT21 were obtained by sequence analysis (see Tables 1 and 2 above).
[0104] 2. Preparation of TCR-Jurkat Cells
[0105] (1) Cell preparation: After counting the CD8+NFAT-GFP+Jurkat cells, each sample was aliquoted into 2×10^5 cells and centrifuged;
[0106] (2) Virus particle dilution: The TCR is packaged into lentivirus, and lentiviral particles expressing the target TCR are prepared according to a 2-fold gradient dilution series;
[0107] (3) Transduction: The cells were resuspended in the diluted lentiviral solution and then seeded into 24-well plates for transduction;
[0108] (4) Medium replacement: One day after transduction, the medium was completely replaced;
[0109] (5) Flow cytometry: Two days after transduction, the expression of TCR on Jurkat cells was detected by flow cytometry; the flow cytometry results showed that TCR could be successfully expressed on the cell membrane surface (see Figure 2 );
[0110] (6) Selection and enrichment of TCR-Jurkat cells: Only TCRJurkat cells with a transduction efficiency between 70% and 80% were selected to ensure consistency and comparability between different TCR constructs; Jurkat cells expressing exogenous TCR were enriched by mTCR for further functional analysis.
[0111] 3. Determination of TCR functional affinity EC50 based on TCR-Jurkat cells
[0112] (1) The different TCR-Jurkat cells prepared above were co-cultured with HLA-A*11:01+K562 cells loaded with gradient dilutions of KRAS-G12V peptide for 24 hours; the specific conditions were as follows: each well contained 5E 4 (5×10^4) Jurkat cells, 5E 4 (5×10^4) K562 cells, the peptide dilution factor is 10, and the final peptide concentration range is 0.1nM to 10μM;
[0113] (2) After washing twice with PBS, flow cytometry was performed to analyze the expression of NFAT-GFP;
[0114] (3) Based on the GFP positivity rate, the EC50 value of each TCR was calculated by determining the peptide concentration that induces 50% of the maximum activation response.
[0115] The results are as follows Figure 3 As shown, the results showed that the affinities of KT18, KT19, KT20 and KT21 were 5 nM, 4 nM, 8.7 nM and 19.4 nM, respectively.
[0116] 4. Preparation of TCR T cells
[0117] (1) Using EasySep TM Human CD8+T cell enrichment kit was used to enrich primary CD8+T cells;
[0118] (2) The enriched CD8 + T cells were activated with anti-CD3 / CD28 T Cell TransAct (MiltenyiBiotec) for 24 h;
[0119] (3) These activated T cells are expressed in KRAS-encoding G12V Transduction was performed with a lentiviral vector expressing a specific TCR; 8 hours after transduction, the culture medium containing IL-7 and IL-15 (10 ng / ml each) was replaced;
[0120] (4) The culture medium was changed every 3 days during the cell culture process;
[0121] (5) After 14 days of culture, T cells were stained with APC-anti-mouse TCRβ chain antibody and analyzed using EasySep TM APC positive selection kit (STEMCELL Technologies) was used to enrich mTCR-positive cells;
[0122] (6) After enrichment, the TCR-T cells are expanded for a second time using feeder cells for 14 days.
[0123] Flow cytometry was used to detect the results. Figure 4 As shown, the results showed that all four TCRs (KT1, KT19, KT20 and KT21) could be stably expressed on the surface of T cells.
[0124] 5. Determination of TCR functional affinity EC50 based on TCR-T cells
[0125] (1) The different TCR-T cells prepared above were co-cultured with HLA-A*11:01+K562 cells loaded with gradient dilutions of KRAS-G12V peptide for 24 hours; the specific conditions were as follows: each well contained 5E 4 (5×10^4) Jurkat cells, 5E 4 (5×10^4) K562 cells, the peptide dilution factor is 10, and the final peptide concentration range is 0.1nM to 10μM;
[0126] (2) Use PE-labeled anti-human CD137 antibody and stain at room temperature in the dark for 10 min;
[0127] (3) After washing twice with PBS, flow cytometry was performed to analyze the expression of CD137;
[0128] (4) Based on the CD137 positivity rate, the EC50 value of each TCR was calculated by determining the peptide concentration that induces 50% of the maximum activation response.
[0129] The results are shown in the figure Figure 5 As shown, the results showed that all four TCRs could be activated by peptides, and the degree of activation increased with the increase of peptide concentration.
[0130] 6. Determination of IFN-γ secretion level of TCR based on TCR-T cells
[0131] (1) The different TCR-T cells prepared above were co-cultured with HLA-A11:01 (KRAS-G12V / HLA-A1101 tetramer) + K562 cells loaded with different concentrations of KRASG12V polypeptide for 24 hours; each well contained 5E 4 (5×10^4) TCR T cells, 5E4 K562 cells;
[0132] (2) ELISA was used to detect the content of cytokine IFN-γ in the supernatant, as follows:
[0133] 1) Use the recommended antibody pair for IFN-γ cytokine quantification, including IFN-γ capture antibody (clone: MD-1, Biolegend) and IFN-γ detection antibody (clone: 4S.B3, Biolegend);
[0134] 2) ELISA plates were coated overnight at 4°C and 50 μl of capture antibody at a concentration of 2 μg / ml was added to each well;
[0135] 3) After coating, wash three times with PBS containing 0.05% Tween-20 (PBS-T) and block with 3% bovine serum albumin (BSA) at room temperature for 1 hour to prevent nonspecific binding;
[0136] 4) Add the supernatant collected from the co-culture of T cells and target cells to the prepared plate, 50 μl per well, and incubate at room temperature for 2 hours to promote the binding of cytokines;
[0137] 5) After incubation, wash the plate three times with PBS-T to remove unbound substances;
[0138] 6) Add the detection antibody diluted to 1 μg / ml to the plate, 50 μl per well, and incubate at room temperature for 1 hour;
[0139] 7) After washing five times again, 50 μl of 1:1000 diluted streptavidin-alkaline phosphatase (Mabtech) was added to each well and incubated at room temperature in the dark for 1 hour;
[0140] 8) After incubation, the plate was washed six times, and then 50 μl of p-nitrophenyl phosphate (pNPP) substrate (Thermo) was added to each well;
[0141] 9) After incubation at 37°C in the dark for 30 minutes, the reaction was terminated by adding 50 μl of stop solution;
[0142] 10) The plate was read at 405 nm (OD405) using a Varioskan LUX multi-mode microplate reader (Thermo);
[0143] 11) Determine the IFN-γ content in the sample by comparing the optical density of the sample with a standard curve of recombinant human IFN-γ of known concentration.
[0144] The results are as follows Figure 6 As shown, the results showed that all four TCRs could be activated by peptides, and the degree of activation increased with the increase of peptide concentration.
[0145] VII. Detection of activation molecule CD137 expression after co-incubation of TCR-T cells with tumor cells
[0146] (1) The different TCR T cells prepared above were co-cultured with HLA-A*11:01+ different tumor cells (COR-L23, HCC827, SW480 and SW620) for 24 hours; each well contained 5E 4 (5×10^4) TCR T cells, 5E 4 (5×10^4) tumor cells; tumor cells that do not express HLA-A*11:01 were set as negative controls;
[0147] (2) Use PE-labeled anti-human CD137 antibody and stain at room temperature in the dark for 10 min;
[0148] (3) After washing twice with PBS, flow cytometry was performed to analyze the expression of CD137.
[0149] Test results such as Figure 7 As shown, the results showed that all TCRs were able to be activated, among which KT18 TCR had the highest activation intensity.
[0150] 8. Detection of the killing ability of TCR-T cells on tumor cells
[0151] The different TCR-T cells prepared above were co-cultured with different tumor cells (COR-L23, HCC827, SW480 and SW620) transduced with the HLA-A11:01 gene and harboring the KRAS-G12V mutation. Each well was treated with 5E 4 (5×10^4) tumor cells, changing the amount of TCR-T cells, thus including different ratios of TCR-T cells to tumor cells (the ratio of TCR-T cells to tumor cells was set to 0.5:1, 1:1, 2.5:1, 5:1 and 10:1); at the same time, tumor cells that were not transduced with the HLA-A11:01 gene were set as controls; the experimental results showed that TCR had no killing ability on tumor cells that were not transduced with the HLA-A11:01 gene ( Figure 8 ), but tumor cells transduced with the HLA-A11:01 gene can be effectively killed by TCR, and the killing ability increases with the increase of the effector-target ratio ( Fig. 9 ).
[0152] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.
Claims
1. A TCR targeting a polypeptide-HLA-A1101 complex, characterized in that: Select from any of the following TCRs: (a) a first TCR comprising an α chain variable region and a β chain variable region, wherein the α chain variable region comprises an α chain CDR1 as shown in SEQ ID NO: 1, an α chain CDR2 as shown in SEQ ID NO: 2, and an α chain CDR3 as shown in SEQ ID NO: 3; and the β chain variable region comprises a β chain CDR1 as shown in SEQ ID NO: 9, a β chain CDR2 as shown in SEQ ID NO: 10, and a β chain CDR3 as shown in SEQ ID NO: 11; (b) a second TCR comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO:33, an α chain CDR2 as shown in SEQ ID NO:34, and an α chain CDR3 as shown in SEQ ID NO:35; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO:41, a β chain CDR2 as shown in SEQ ID NO:42, and a β chain CDR3 as shown in SEQ ID NO:43; (c) a third TCR comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO:65, an α chain CDR2 as shown in SEQ ID NO:66, and an α chain CDR3 as shown in SEQ ID NO:67; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO:73, a β chain CDR2 as shown in SEQ ID NO:74, and a β chain CDR3 as shown in SEQ ID NO:75; (d) A fourth TCR comprising an α chain variable region and a β chain variable region, the α chain variable region comprising an α chain CDR1 as shown in SEQ ID NO:97, an α chain CDR2 as shown in SEQ ID NO:98, and an α chain CDR3 as shown in SEQ ID NO:99; the β chain variable region comprising a β chain CDR1 as shown in SEQ ID NO:105, a β chain CDR2 as shown in SEQ ID NO:106, and a β chain CDR3 as shown in SEQ ID NO:
107.
2. The TCR according to claim 1, characterized in that In the first TCR, the α chain variable region further comprises: one or more of the α chain FR1 as shown in SEQ ID NO:4, the α chain FR2 as shown in SEQ ID NO:5, the α chain FR3 as shown in SEQ ID NO:6, and the α chain FR4 as shown in SEQ ID NO:7; the β chain variable region further comprises: one or more of the β chain FR1 as shown in SEQ ID NO:12, the β chain FR2 as shown in SEQ ID NO:13, the β chain FR3 as shown in SEQ ID NO:14, and the β chain FR4 as shown in SEQ ID NO:15; In the second TCR, the α chain variable region further comprises: one or more of the α chain FR1 as shown in SEQ ID NO:36, the α chain FR2 as shown in SEQ ID NO:37, the α chain FR3 as shown in SEQ ID NO:38, and the α chain FR4 as shown in SEQ ID NO:39; the β chain variable region further comprises: one or more of the β chain FR1 as shown in SEQ ID NO:44, the β chain FR2 as shown in SEQ ID NO:45, the β chain FR3 as shown in SEQ ID NO:46, and the β chain FR4 as shown in SEQ ID NO:47; In the third TCR, the α chain variable region further comprises: one or more of the α chain FR1 as shown in SEQ ID NO:68, the α chain FR2 as shown in SEQ ID NO:69, the α chain FR3 as shown in SEQ ID NO:70, and the α chain FR4 as shown in SEQ ID NO:71; the β chain variable region further comprises: one or more of the β chain FR1 as shown in SEQ ID NO:76, the β chain FR2 as shown in SEQ ID NO:77, the β chain FR3 as shown in SEQ ID NO:78, and the β chain FR4 as shown in SEQ ID NO:79; In the fourth TCR, the α chain variable region further includes: one or more of the α chain FR1 as shown in SEQ ID NO:100, the α chain FR2 as shown in SEQ ID NO:101, the α chain FR3 as shown in SEQ ID NO:102, and the α chain FR4 as shown in SEQ ID NO:103; the β chain variable region further includes: one or more of the β chain FR1 as shown in SEQ ID NO:108, the β chain FR2 as shown in SEQ ID NO:109, the β chain FR3 as shown in SEQ ID NO:110, and the β chain FR4 as shown in SEQ ID NO:
111.
3. The TCR according to claim 1 or 2, characterized in that The α chain variable region of the first TCR comprises the sequence shown in SEQ ID NO:8; the β chain variable region comprises the sequence shown in SEQ ID NO:16; The α chain variable region of the second TCR comprises the sequence shown in SEQ ID NO:40; the β chain variable region comprises the sequence shown in SEQ ID NO:48; The α chain variable region of the third TCR comprises the sequence shown in SEQ ID NO:72; the β chain variable region comprises the sequence shown in SEQ ID NO:80; The α chain variable region of the fourth TCR comprises the sequence shown in SEQ ID NO:104; the β chain variable region comprises the sequence shown in SEQ ID NO:
112.
4. An antigen-binding fragment, characterized in that Comprising the TCR according to any one of claims 1 to 3.
5. A polynucleotide, characterized in that Encoding the TCR as claimed in any one of claims 1 to 4.
6. The polynucleotide according to claim 5, characterized in that The polynucleotide is selected from any one of the following nucleotides: (a) the polynucleotide encoding the first TCR comprises the sequence shown in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 26 or SEQ ID NO: 27; (b) the polynucleotide encoding the second TCR comprises a sequence as shown in SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:58 or SEQ ID NO:59; (c) the polynucleotide encoding the third TCR comprises the sequence shown in SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:89, SEQ ID NO:90 or SEQ ID NO:91; (d) The polynucleotide encoding the fourth TCR comprises the sequence shown in SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:121, SEQ ID NO:122 or SEQ ID NO:
123.
7. The polynucleotide according to claim 6, characterized in that (a) the polynucleotide encoding the first TCR further comprises one or more of the sequences shown in SEQ ID NO: 20 to SEQ ID NO: 23, SEQ ID NO: 28 to SEQ ID NO: 31; (b) the polynucleotide encoding the second TCR further comprises one or more of the sequences shown in SEQ ID NO:52 to SEQ ID NO:55, SEQ ID NO:60 to SEQ ID NO:63; (c) the polynucleotide encoding the third TCR further comprises one or more of the sequences shown in SEQ ID NO:84 to SEQ ID NO:87, SEQ ID NO:92 to SEQ ID NO:95; (d) The polynucleotide encoding the fourth TCR further comprises one or more of the sequences shown in SEQ ID NO:116 to SEQ ID NO:119 and SEQ ID NO:124 to SEQ ID NO:
127.
8. The polynucleotide according to claim 6 or 7, characterized in that The polynucleotide encoding the first TCR comprises the sequences shown in SEQ ID NO: 24 and SEQ ID NO: 32; The polynucleotide encoding the second TCR comprises the sequences shown in SEQ ID NO:56 and SEQ ID NO:64; The polynucleotide encoding the third TCR comprises the sequences shown in SEQ ID NO: 88 and SEQ ID NO: 96; The polynucleotide encoding the fourth TCR comprises the sequences shown in SEQ ID NO:120 and SEQ ID NO:
128.
9. An expression vector, characterized in that Comprising the polynucleotide according to any one of claims 5 to 8.
10. An engineered cell, characterized in that Comprising the expression vector according to claim 9.
11. A pharmaceutical composition, characterized in that Comprising the TCR according to any one of claims 1 to 3, the antigen binding fragment according to claim 4, the polynucleotide according to any one of claims 5 to 8, the expression vector according to claim 9, or the engineered cell according to claim 10, and a pharmaceutically acceptable carrier and / or diluent.
12. Use of the TCR according to any one of claims 1 to 3, the antigen-binding fragment according to claim 4, the polynucleotide according to any one of claims 5 to 8, the expression vector according to claim 9, or the engineered cell according to claim 10 in the preparation of a reagent or kit for detecting tumor cells expressing the KRAS-G12V mutation.
13. Use of the TCR according to any one of claims 1 to 3, the antigen-binding fragment according to claim 4, the polynucleotide according to any one of claims 5 to 8, the expression vector according to claim 9, or the engineered cell according to claim 10 in the preparation of a drug for treating cancer; cancer includes pancreatic cancer, colon cancer, endometrial cancer, lung cancer, bile duct cancer, cervical cancer or bladder cancer.
14. The use according to claim 13, characterized in that Drugs used to treat cancer include protein drugs, ADC drugs, or TCR and antigen combination drugs.
Citation Information
Patent Citations
TCR or antigen binding fragment thereof and application thereof
CN115109139A
